PharmaShots Weekly Snapshot (September 30–October 04, 2019)


1. Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B

Published: Oct 03, 2019 | Tags: Arbutus, Discontinue, P-Ia/Ib, Clinical Study, AB-506, Chronic Hepatitis B

2. Janssen’s Niraparib Receives the US FDA’s Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer

Published: Oct 03, 2019 | Tags: Janssen, Niraparib, Receives, US, FDA, Breakthrough Therapy Designation, Metastatic Castration-Resistant Prostate Cancer

3. Silver Cloud Health Partners with Microsoft to Deploy AI for Enhancing its Digital Mental Healthcare

Published: Oct 02, 2019 | Tags: Silver Cloud Health, Partners, Microsoft, Deploy, AI, Digital Mental Healthcare

4. AstraZeneca’s Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA’s Approval for Severe Eosinophilic Asthma

Published: Oct 04, 2019 | Tags: AstraZeneca, Fasenra Pen, Pre-Filled Auto-Injector, Receives, US, FDA, Approval, Severe Eosinophilic Asthma

5.Gilead’s Descovy Receives the US FDA’s Approval for HIV Pre-Exposure Prophylaxis

Published: Oct 03, 2019 | Tags: Gilead, Descovy, Receives, US, FDA, Approval, HIV Pre-Exposure Prophylaxis

6. Takeda Signs a License Agreement with Goldfinch Bio for its GFB-024 to Treat Rare and Metabolic Kidney Diseases

Published: Oct 03, 2019 | Tags: Takeda, Signs, License Agreement, Goldfinch Bio, GFB-024, Rare and Metabolic Kidney Diseases

7. Novo Nordisk Collaborates with Noom to Provide Digital Health Solutions Targeting Weight Management in Patients with Obesity

Published: Oct 01, 2019 | Tags: Novo Nordisk, Collaborates, Noom, Digital Health Solutions, Weight Management, Patients, Obesity

8. Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada

Published:  Oct 02, 2019 | Tags: Eli Lilly, Reports, Availability, Emgality, galcanezumab, Prevent, Migraine, Canada

9. Merck’s Keytruda Receives NMPA’s Approval as Monotherapy for 1L Treatment of Advanced Non-Small Cell Lung Cancer with PD-L1 Tumor Expression in China

Published: Oct 02, 2019 | Tags: Merck, Keytruda, Receives, NMPA, Approval, Monotherapy, 1L, Advanced Non-Small Cell Lung Cancer, PD-L1 Tumor Expression, China

10. Eli Lilly Reports Results of Taltz (ixekizumab) in Head-to-Head P-IV IXORA-R Study for Moderate to Severe Plaque Psoriasis

Published: Oct 02, 2019 | Tags: Eli Lilly, Reports, Results, Taltz, ixekizumab, Head-to-Head, P-IV, IXORA-R, Study, Moderate to Severe Plaque Psoriasis

11. Philips Collaborates with Air Ambulance Kent Surrey Sussex to Provide Emergency Services in the UK

Published: Oct 03, 2019 | Tags: Philips, Collaborates, Air Ambulance Kent Surrey Sussex, Provide, Emergency Services, UK

12. Biocon and Mylan Launch Semglee (biosimilar, Insulin Glargine) in Australia

Published: Oct 03, 2019 | Tags: Biocon, Mylan, Launch, Semglee, biosimilar, Insulin Glargine, Australia

13. Novartis Signs a Multiyear Agreement with Microsoft to Transform Medicine with the Launch of AI Innovation Lab

Published: Oct 01, 2019 | Tags: Novartis, Signs, Multiyear Agreement, Microsoft, Reimagining Medicine, Launch, Novartis, AI Innovation Lab

14. Pfizer to Launch its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019

Published: Sept 30, 2019 | Tags: Pfizer, Launch, Zirabev, Biosimliar, Bevacizumab, US, 2019

15.Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

Published: Oct 01, 2019 | Tags: Eisai, Signs, Research, Option Agreement, Numab, Discover, Develop, Multi-Specific Antibody, Immunotherapies, Cancer

16. Taisho Signs an Exclusive License Agreement with Moberg Pharma to Develop and Commercialize MOB-015 in Japan

Published: Oct 01, 2019 | Tags: Taisho, Signs, Exclusive, License Agreement, Moberg Pharma, Develop, Commercialize, MOB-015, Japan

17. Roche Reports Result of Tecentriq (atezolizumab) + Platinum-Based CT in P-III IMvigor130 Study for Advanced Bladder Cancer

Published: Sept 30, 2019 | Tags: Roche, Reports, Result, Tecentriq, atezolizumab, P-III, IMvigor130 Study, Advanced Bladder Cancer

18.Janssen’s Invokana (canagliflozin) Receives the US FDA’s Approval for Patients with Type 2 Diabetes and Diabetic Kidney Disease

Published: Oct 01, 2019 | Tags: Janssen, Invokana, canagliflozin, Receives, US, FDA, Approval, Type 2 Diabetes, Diabetic Kidney Disease

19. AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm

Published: Oct 01, 2019 | Tags: AstraZeneca, Divest, Worldwide, Commercialization, Rights, Losec, omeprazole, Cheplapharm

20. SymBio Signs Worldwide Exclusive License Agreement with Chimerix to Develop and Commercialize Brincidofovir

Published: Sept 30, 2019 | Tags: SymBio, Signs, Worldwide, Exclusive, License Agreement, Chimerix, Develop, Commercialize, Brincidofovir

21. Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia

Published: Sept 30, 2019 | Tags: Celltrion, Co-Marketing Agreement, Juno, Australia

22. Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates

Published: Sept 30, 2019 | Tags: Vertex, Collaborates, Ribometrix, Discover, Develop, Three, RNA Targeted Candidates

23.Merck Reports Results of Recarbrio (imipenem/cilastatin/relebactam) in P-III RESTORE-IMI 2 Study for Patients with HABP/VABP

Published: Sept 30, 2019 | Tags: Merck, Reports, Results, Recarbrio, imipenem, cilastatin, relebactam, P-III, RESTORE-IMI 2, HABP, VABP

24. GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

Published: Sept 30, 2019 | Tags: GSK, Reports, Results, Nucala, mepolizumab, REALITI-A, Severe Eosinophilic Asthma

25.Roche’s Rituxan (rituximab) Receives the US FDA’s Approval for Two Rare Blood Vessel Disorders in Pediatric Patients Aged 2yrs. and Above

Published: Sept 30, 2019 | Tags: Roche, Rituxan, rituximab, Receives, US, FDA, Approval, Two, Rare Blood Vessel Disorders, Pediatric Patients

26.Sobi to Acquire Dova Pharmaceuticals for $915M

Published: Sept 30, 2019 | Tags: Sobi, Acquire, Dova Pharmaceuticals, $915M